No Interferon in Phase 3 Trials of Hep C Drug PSI-7977
Share
Follow Us
November 1, 2011
Hep C Inhibitor PSI-7977 Goes Interferon-Free in Phase III Studies
Princeton, New Jersey-based Pharmasset is putting its lead experimental hepatitis C nucleotide inhibitor to the test in three late-stage clinical trials exploring the drug’s safety and efficacy as a component of a regimen that only needs to be taken for three months and that doesn’t include pegylated interferon, according to a November 1 announcement by the company. If all goes well in the studies, the company will petition the U.S. Food and Drug Administration (FDA) to begin the process of reviewing PSI-7977 for approval sometime in the second half of 2013.
Continue reading this entire article:
http://www.aidsmeds.com/articles/pharmasset_psi7977_trials_1667_21386.shtml
